Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end report that it's in a stronger position going into 2025 thanks to improved ...

Swiss Biotechnology firm Lonza, which purchased the Genentech facility in Vacaville last year, reported an income of 6.6 billion in Swiss francs (CHF) for the year 2024, which converts to about $7 ...

Lonza LONN-1.49%decrease; red down pointing triangle Group posted lower sales and earnings in 2024 due to slower demand for its capsules business which it expects to return to growth this year ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing ...

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia ...

Investing.com -- Shares of Lonza Group AG (SIX:LONN) fell more than 3% on Wednesday after the company reported full-year 2024 earnings that showed flat revenue growth and a dip in overall sales ...